Merck and Moderna said the vaccine helped prevent the return and spread of melanoma in a large trial involving more than 1,000 patients.

Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations…

The experimental vaccine successfully reduced the recurrence of melanoma, the company said